Please select the option that best describes you:

In 2024, do you consider isolated gain(1q) [not amp(1q)] to be a high-risk cytogenetic abnormality in multiple myeloma?  

Most would argue that gain(1q) in combination with another high-risk feature constitutes ultra-high-risk multiple myeloma, and most would argue (with FORTE being a good example) that amp(1q) is a high-risk feature. What about patients who have exactly 3 copies of 1q and no other high-risk features?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at University of Washington, Fred Hutchinson Cancer Research Center
Brilliantly stated - I love the unofficial idea of...
Medical Oncologist at Winship Cancer Institute of Emory University
I agree with what has been written to date. My onl...
Sign in or Register to read more